|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EIF3A |
Gene summary for EIF3A |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EIF3A | Gene ID | 8661 |
| Gene name | eukaryotic translation initiation factor 3 subunit A | |
| Gene Alias | EIF3 | |
| Cytomap | 10q26.11 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q14152 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 8661 | EIF3A | HTA11_3410_2000001011 | Human | Colorectum | AD | 6.74e-07 | -4.30e-01 | 0.0155 |
| 8661 | EIF3A | HTA11_347_2000001011 | Human | Colorectum | AD | 1.43e-15 | 7.28e-01 | -0.1954 |
| 8661 | EIF3A | HTA11_1391_2000001011 | Human | Colorectum | AD | 3.24e-04 | 6.57e-01 | -0.059 |
| 8661 | EIF3A | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.13e-08 | 5.29e-01 | 0.0674 |
| 8661 | EIF3A | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 5.13e-14 | 1.48e+00 | 0.3487 |
| 8661 | EIF3A | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.29e-15 | 9.98e-01 | 0.281 |
| 8661 | EIF3A | A002-C-010 | Human | Colorectum | FAP | 4.17e-02 | -1.48e-01 | 0.242 |
| 8661 | EIF3A | A015-C-203 | Human | Colorectum | FAP | 8.86e-23 | -2.25e-01 | -0.1294 |
| 8661 | EIF3A | A015-C-204 | Human | Colorectum | FAP | 6.32e-04 | -1.73e-01 | -0.0228 |
| 8661 | EIF3A | A014-C-040 | Human | Colorectum | FAP | 3.17e-03 | -3.37e-01 | -0.1184 |
| 8661 | EIF3A | A002-C-201 | Human | Colorectum | FAP | 2.15e-10 | -2.57e-01 | 0.0324 |
| 8661 | EIF3A | A001-C-119 | Human | Colorectum | FAP | 2.87e-12 | 4.78e-01 | -0.1557 |
| 8661 | EIF3A | A001-C-108 | Human | Colorectum | FAP | 5.01e-13 | 7.96e-02 | -0.0272 |
| 8661 | EIF3A | A002-C-205 | Human | Colorectum | FAP | 5.94e-20 | 1.64e-01 | -0.1236 |
| 8661 | EIF3A | A001-C-104 | Human | Colorectum | FAP | 7.99e-05 | 1.86e-01 | 0.0184 |
| 8661 | EIF3A | A015-C-006 | Human | Colorectum | FAP | 8.41e-19 | 3.28e-01 | -0.0994 |
| 8661 | EIF3A | A015-C-106 | Human | Colorectum | FAP | 5.10e-06 | -4.34e-02 | -0.0511 |
| 8661 | EIF3A | A002-C-114 | Human | Colorectum | FAP | 3.57e-16 | 5.50e-02 | -0.1561 |
| 8661 | EIF3A | A015-C-104 | Human | Colorectum | FAP | 2.54e-32 | 7.17e-02 | -0.1899 |
| 8661 | EIF3A | A001-C-014 | Human | Colorectum | FAP | 7.96e-08 | -8.77e-02 | 0.0135 |
| Page: 1 2 3 4 5 6 7 8 9 10 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
| GO:00160327 | Liver | NAFLD | viral process | 80/1882 | 415/18723 | 7.71e-09 | 1.07e-06 | 80 |
| GO:00226137 | Liver | NAFLD | ribonucleoprotein complex biogenesis | 76/1882 | 463/18723 | 1.19e-05 | 3.67e-04 | 76 |
| GO:00226187 | Liver | NAFLD | ribonucleoprotein complex assembly | 42/1882 | 220/18723 | 3.40e-05 | 8.80e-04 | 42 |
| GO:00718267 | Liver | NAFLD | ribonucleoprotein complex subunit organization | 42/1882 | 227/18723 | 7.21e-05 | 1.51e-03 | 42 |
| GO:00190806 | Liver | NAFLD | viral gene expression | 21/1882 | 94/18723 | 3.49e-04 | 5.32e-03 | 21 |
| GO:00064137 | Liver | NAFLD | translational initiation | 22/1882 | 118/18723 | 3.18e-03 | 2.84e-02 | 22 |
| GO:00021837 | Liver | NAFLD | cytoplasmic translational initiation | 9/1882 | 34/18723 | 5.27e-03 | 4.08e-02 | 9 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:002261312 | Liver | Cirrhotic | ribonucleoprotein complex biogenesis | 231/4634 | 463/18723 | 3.28e-32 | 6.86e-29 | 231 |
| GO:001603212 | Liver | Cirrhotic | viral process | 203/4634 | 415/18723 | 5.40e-27 | 3.76e-24 | 203 |
| GO:000641312 | Liver | Cirrhotic | translational initiation | 76/4634 | 118/18723 | 8.36e-20 | 2.18e-17 | 76 |
| GO:007182612 | Liver | Cirrhotic | ribonucleoprotein complex subunit organization | 115/4634 | 227/18723 | 2.67e-17 | 3.63e-15 | 115 |
| GO:002261812 | Liver | Cirrhotic | ribonucleoprotein complex assembly | 112/4634 | 220/18723 | 4.35e-17 | 5.81e-15 | 112 |
| GO:001908011 | Liver | Cirrhotic | viral gene expression | 52/4634 | 94/18723 | 2.19e-10 | 1.08e-08 | 52 |
| GO:000218312 | Liver | Cirrhotic | cytoplasmic translational initiation | 26/4634 | 34/18723 | 3.38e-10 | 1.63e-08 | 26 |
| GO:00017327 | Liver | Cirrhotic | formation of cytoplasmic translation initiation complex | 13/4634 | 16/18723 | 3.31e-06 | 5.74e-05 | 13 |
| GO:00190816 | Liver | Cirrhotic | viral translation | 13/4634 | 16/18723 | 3.31e-06 | 5.74e-05 | 13 |
| GO:00755226 | Liver | Cirrhotic | IRES-dependent viral translational initiation | 10/4634 | 11/18723 | 7.30e-06 | 1.13e-04 | 10 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EIF3A | SNV | Missense_Mutation | novel | c.2263N>A | p.Glu755Lys | p.E755K | Q14152 | protein_coding | tolerated(0.27) | benign(0.19) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| EIF3A | SNV | Missense_Mutation | rs771425860 | c.3593N>T | p.Ser1198Leu | p.S1198L | Q14152 | protein_coding | tolerated_low_confidence(0.07) | benign(0.011) | TCGA-BH-A0AW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD |
| EIF3A | SNV | Missense_Mutation | c.4145G>A | p.Arg1382His | p.R1382H | Q14152 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.991) | TCGA-BH-A18L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| EIF3A | SNV | Missense_Mutation | novel | c.3472N>G | p.Pro1158Ala | p.P1158A | Q14152 | protein_coding | tolerated_low_confidence(0.2) | benign(0.138) | TCGA-C8-A3M7-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| EIF3A | SNV | Missense_Mutation | novel | c.1749G>C | p.Glu583Asp | p.E583D | Q14152 | protein_coding | deleterious(0.01) | probably_damaging(0.97) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| EIF3A | SNV | Missense_Mutation | novel | c.2906N>C | p.Arg969Thr | p.R969T | Q14152 | protein_coding | deleterious(0.02) | possibly_damaging(0.628) | TCGA-OL-A5RW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| EIF3A | insertion | In_Frame_Ins | novel | c.1994_1995insAAATAATGCCGCTCCAGTTCC | p.Asp665delinsGluAsnAsnAlaAlaProValPro | p.D665delinsENNAAPVP | Q14152 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| EIF3A | insertion | Frame_Shift_Ins | novel | c.1617_1618insAAGA | p.Ala540LysfsTer21 | p.A540Kfs*21 | Q14152 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| EIF3A | insertion | Frame_Shift_Ins | novel | c.1615_1616insTGGGTGC | p.Pro539LeufsTer23 | p.P539Lfs*23 | Q14152 | protein_coding | TCGA-A8-A07R-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Ancillary | zoledronic | SD | ||
| EIF3A | deletion | Frame_Shift_Del | novel | c.2944delG | p.Ala982GlnfsTer191 | p.A982Qfs*191 | Q14152 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 8661 | EIF3A | NA | Platinum compounds | |||
| 8661 | EIF3A | NA | carboplatin | CARBOPLATIN | 23127338 | |
| 8661 | EIF3A | NA | cisplatin | CISPLATIN | 23127338 |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |